Cargando…

Chimeric antigen receptor T-cell therapy

Chimeric antigen receptor T-cell therapies are promising new options for patients with relapsed or refractory diffuse large B-cell lymphoma or acute lymphoblastic leukaemia. They increase complete response rates and the chances of achieving prolonged remission. Chimeric antigen receptor T cells are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burge, Cale, Vanguru, Vinay, Ho, Phoebe Joy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Therapeutic Guidelines 2023
Materias:	Experimental and Clinical Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664099/ http://dx.doi.org/10.18773/austprescr.2023.003

Ejemplares similares

Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
por: Hernández-López, Alejandrina, et al.
Publicado: (2021)

Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme
por: Marei, Hany E., et al.
Publicado: (2021)

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
por: Guo, Xingliang, et al.
Publicado: (2018)

BAY 60-6583 Enhances the Antitumor Function of Chimeric Antigen Receptor-Modified T Cells Independent of the Adenosine A2b Receptor
por: Tang, Jiaxing, et al.
Publicado: (2021)

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
por: Reinhardt, Bryanna, et al.
Publicado: (2023)

Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015)

Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies: A Systematic Review
por: Banerjee, Rahul, et al.
Publicado: (2021)

Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells
por: SAKAI, Osamu, et al.
Publicado: (2021)

The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
por: Gargett, Tessa, et al.
Publicado: (2014)

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
por: Johnsrud, Andrew, et al.
Publicado: (2021)

Chimeric Antigen Receptor Therapy for B-cell Malignancies
por: Porter, David L, et al.
Publicado: (2011)

Chimeric antigen receptor T-cell therapy for solid tumors
por: Newick, Kheng, et al.
Publicado: (2016)

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

Chimeric antigen receptor T cell therapy for multiple myeloma
por: Hasegawa, Kana, et al.
Publicado: (2019)

Mechanisms of failure of chimeric antigen receptor T-cell therapy
por: Li, Xiaoqing, et al.
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
por: Hosen, Naoki
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
por: Sur, Daniel, et al.
Publicado: (2020)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Chimeric antigen receptor‐T cell therapies: The changing landscape
por: Sengsayadeth, Salyka M., et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
por: Ying, Zhitao, et al.
Publicado: (2022)

Chimeric antigen receptors in the brain: Can we tackle glioblastoma with engineered NK cells?
por: Roth, Patrick
Publicado: (2023)

Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials
por: Hu, Dingyuan, et al.
Publicado: (2023)

Role of bridging therapy during chimeric antigen receptor T cell therapy
por: Bhaskar, Shakthi T., et al.
Publicado: (2021)

Thrombotic microangiopathy following chimeric antigen receptor T-cell therapy
por: Wu, Matthew S., et al.
Publicado: (2023)

Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma
por: Uslu, Ugur, et al.
Publicado: (2023)

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
por: Pang, Yanyu, et al.
Publicado: (2018)

Is Chimeric Antigen Receptor T-cell Therapy the Future of Autoimmunity Management?
por: Tahir, Amber
Publicado: (2018)

Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
por: Li, Hua, et al.
Publicado: (2017)

Switching on the green light for chimeric antigen receptor T‐cell therapy
por: Mardiana, Sherly, et al.
Publicado: (2019)

Biomarkers in individualized management of chimeric antigen receptor T cell therapy
por: Du, Mengyi, et al.
Publicado: (2020)

Cardiovascular Risk Profile of Chimeric Antigen Receptor T-cell Therapy
por: Ahmed, Talha
Publicado: (2020)

Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer
por: Yan, Wenying, et al.
Publicado: (2019)

The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
por: Marks, Peter
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020)

Fusarium rhinosinusitis post chimeric antigen receptor T-cell therapy
por: Chesdachai, Supavit, et al.
Publicado: (2021)

Chimeric non-antigen receptors in T cell-based cancer therapy
por: Guo, Jitao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a65jkilrgdbsio7s5ip1i8kjkv